{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:11:55Z","timestamp":1785726715778,"version":"3.56.0"},"reference-count":34,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:00:00Z","timestamp":1715385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>Chronic migraine (CM) significantly affects underage individuals. The study objectives are (1) to analyze the effectiveness and safety of onabotulinumtoxinA (BTX-A) in adolescents with CM; (2) to review the literature on BTX-A use in the pediatric population. This prospective observational study included patients under 18 years old with CM treated with BTX-A (PREEMPT protocol) as compassionate use. Demographic, efficacy (monthly headache days\u2014MHD; monthly migraine days\u2014MMD; acute medication days\/month\u2014AMDM) and side effect data were collected. A \u2265 50% reduction in MHD was considered as a response. Effectiveness and safety were analyzed at 6 and 12 months. A systematic review of the use of BTX-A in children\/adolescents was conducted in July 2023. In total, 20 patients were included (median age 15 years [14.75\u201317], 70% (14\/20) females). The median basal frequencies were 28.8 [20\u201328] MHD, 18 [10\u201328] MMD and 10 [7.5\u201321.2] AMDM. Compared with baseline, at 6 months (n = 20), 11 patients (55%) were responders, with a median reduction in MHD of \u221220 days\/month (p = 0.001). At 12 months (n = 14), eight patients (57.1%) were responders, with a median reduction in MHD of \u221217.5 days\/month (p = 0.002). No adverse effects were reported. The literature search showed similar results. Our data supports the concept that BTX-A is effective, well tolerated, and safe in adolescents with CM resistant to oral preventatives.<\/jats:p>","DOI":"10.3390\/toxins16050221","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T09:28:25Z","timestamp":1715592505000},"page":"221","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effectiveness and Safety of OnabotulinumtoxinA in Adolescent Patients with Chronic Migraine"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8119-7489","authenticated-orcid":false,"given":"Laura","family":"G\u00f3mez-Dab\u00f3","sequence":"first","affiliation":[{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron Hospital, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Caronna","sequence":"additional","affiliation":[{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron Hospital, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rut","family":"Mas-de-les-Valls","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3042-2007","authenticated-orcid":false,"given":"V\u00edctor J.","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Alpuente","sequence":"additional","affiliation":[{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron Hospital, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2856-4134","authenticated-orcid":false,"given":"Marta","family":"Torres-Ferrus","sequence":"additional","affiliation":[{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron Hospital, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Pozo-Rosich","sequence":"additional","affiliation":[{"name":"Headache Clinic, Neurology Department, Vall d\u2019Hebron Hospital, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"},{"name":"Headache and Neurological Pain Research Group, Vall d\u2019Hebron Institut de Recerca (VHIR), Department of Medicine, Universitat Aut\u00f2noma de Barcelona, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s10194-023-01541-0","article-title":"European Headache Federation School of Advanced Studies (EHF-SAS). Primary headache epidemiology in children and adolescents: A systematic review and meta-analysis","volume":"24","author":"Onofri","year":"2023","journal-title":"J. Headache Pain."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1177\/0333102409355601","article-title":"Migraine prevalence by age and sex in the United States: A life-span study","volume":"30","author":"Victor","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fneur.2020.00594","article-title":"Impact of Puberty in Girls on Prevalence of Primary Headache Disorder Among Female Schoolchildren in Kuwait","volume":"11","author":"Alashqar","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/0333102418777509","article-title":"Headache, comorbidities and lifestyle in an adolescent population (The TEENs Study)","volume":"39","author":"Quintana","year":"2019","journal-title":"Cephalalgia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.braindev.2021.04.004","article-title":"Emotional and behavioral problems in pediatric patients with migraine and tension-type headache","volume":"43","author":"Shimomura","year":"2021","journal-title":"Brain Dev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00787-020-01599-0","article-title":"Headache and mental disorders in a nationally representative sample of American youth","volume":"31","author":"Hommer","year":"2022","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/0333102414547134","article-title":"Relationship of childhood headaches with preferences in leisure time activities, depression, anxiety and eating habits: A population-based, cross-sectional study","volume":"35","author":"Aysev","year":"2015","journal-title":"Cephalalgia"},{"key":"ref_8","unstructured":"GBD 2019 Diseases and Injuries Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204\u20131222."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.0000000000008105","article-title":"Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society","volume":"93","author":"Oskoui","year":"2019","journal-title":"Neurology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1129-2377-15-15","article-title":"The evolution of headache from childhood to adulthood: A review of the literature","volume":"15","author":"Antonaci","year":"2014","journal-title":"J. Headache Pain."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1177\/03331024221123058","article-title":"Effectiveness of onabotulinumtoxinA (BOTOX\u00ae) for the preventive treatment of chronic migraine: A meta-analysis on 10 years of real-world data","volume":"42","author":"Ducros","year":"2022","journal-title":"Cephalalgia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/head.13653","article-title":"FORWARD Study: Evaluating the Comparative Effectiveness of Onabotulinumtoxina and Topiramate for Headache Prevention in Adults With Chronic Migraine","volume":"59","author":"Rothrock","year":"2019","journal-title":"Headache"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J. Headache Pain."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/head.13754","article-title":"A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine","volume":"60","author":"Winner","year":"2020","journal-title":"Headache"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/rapm-2020-101605","article-title":"Effectiveness of onabotulinumtoxinA (BOTOX) in pediatric patients experiencing migraines: A randomized, double-blinded, placebo-controlled crossover study in the pediatric pain population","volume":"46","author":"Shah","year":"2021","journal-title":"Reg. Anesth. Pain. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Papetti, L., Frattale, I., Ursitti, F., Sforza, G., Monte, G., Ferilli, M.A.N., Tarantino, S., Proietti Checchi, M., and Valeriani, M. (2023). Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age. J. Clin. Med., 12.","DOI":"10.3390\/jcm12051802"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1055\/a-1832-9168","article-title":"Is Botox Right for Me: When to Assess the Efficacy of the Botox Injection for Chronic Migraine in Pediatric Population","volume":"53","author":"Goenka","year":"2022","journal-title":"Neuropediatrics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.pmn.2023.04.006","article-title":"OnabotulinumtoxinA for Pediatric Migraine","volume":"24","author":"Karian","year":"2023","journal-title":"Pain. Manag. Nurs."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0032-1329612","article-title":"Ten-year follow-up in a case series of integrative botulinum toxin intervention in adolescents with chronic daily headache and associated muscle pain","volume":"43","author":"Schroeder","year":"2012","journal-title":"Neuropediatrics"},{"key":"ref_22","first-page":"151","article-title":"Experience of Botulinum Toxin A Injections for Chronic Migraine Headaches in a Pediatric Chronic Pain Clinic","volume":"26","author":"Santana","year":"2021","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1177\/0883073818776142","article-title":"Onabotulinumtoxin A (BOTOX\u00ae) for ProphylaCTIC Treatment of Pediatric Migraine: A Retrospective Longitudinal Analysis","volume":"33","author":"Shah","year":"2018","journal-title":"J. Child. Neurol."},{"key":"ref_24","first-page":"e4343","article-title":"Further Evidence that Onabotulinum Toxin is a Viable Treatment Option for Pediatric Chronic Migraine Patients","volume":"11","author":"Ali","year":"2019","journal-title":"Cureus"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/head.13317","article-title":"The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients","volume":"58","author":"Chen","year":"2018","journal-title":"Headache"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/head.13359","article-title":"Decreased Pulmonary Function During Botulinum Toxin A Therapy for Chronic Migraines in a 17-Year-Old Female","volume":"58","author":"Oliver","year":"2018","journal-title":"Headache"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pediatrneurol.2022.02.002","article-title":"Generalized Anxiety Disorder: A Predictor for Poor Responsiveness to Botulinum Toxin Type A Therapy for Pediatric Migraine","volume":"130","author":"Goenka","year":"2022","journal-title":"Pediatr. Neurol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.pediatrneurol.2010.06.001","article-title":"Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache","volume":"43","author":"Ahmed","year":"2010","journal-title":"Pediatr. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JNN.0b013e3181aaa98f","article-title":"Botox treatment for migraine and chronic daily headache in adolescents","volume":"41","author":"Chan","year":"2009","journal-title":"J. Neurosci. Nurs."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1526-4610.2010.01766.x","article-title":"Method of injection of onabotulinumtoxinA for chronic migraine: A safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program","volume":"50","author":"Blumenfeld","year":"2010","journal-title":"Headache"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","article-title":"Medication overuse headache","volume":"9","author":"Ashina","year":"2023","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Olesen","year":"2018","journal-title":"Cephalalgia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13643-018-0915-2","article-title":"The risk of bias in observational studies of exposures (ROBINS-E) tool: Concerns arising from application to observational studies of exposures","volume":"7","author":"Bero","year":"2018","journal-title":"Syst. Rev."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/5\/221\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:44:09Z","timestamp":1760107449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/16\/5\/221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,11]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["toxins16050221"],"URL":"https:\/\/doi.org\/10.3390\/toxins16050221","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,11]]}}}